News

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Scholar Rock Reports Preclinical Data on the Therapeutic Benefit of SRK-015 in Models of SMA

    Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the publication, “Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy” in the peer-reviewed journal Human Molecular Genetics. The publication details preclinical studies demonstrating that a highly specific […]

    READ MORE

  2. Novel protective gene for SMA opens new therapeutic options

    The research group of Prof. Dr. Brunhilde Wirth, Head of the Institute of Human Genetics at the University Hospital Cologne and Chair of our Scientific Advisory Board, succeeded to identify calcineurin-like EF-hand Protein 1 (CHP1) reduction as a novel protective modifier for SMA. The results of this study have been published in Brain, an international highly renowned journal. […]

    READ MORE

  3. SMA Europe awards new research grants through its 9th call for research proposals

    SMA research receives vital funds from SMA Europe. Based on the recommendations received by its Scientific Advisory Board, SMA Europe awarded a total of €357,800 Euros to 3 cutting-edge SMA research projects through its 9th Call for Research Proposals. The Scientific Advisory Board reviewed and scored 21 very high level SMA research proposals. As only […]

    READ MORE

  4. SMA Europe organises first European SMA Research Conference!

    SMA Europe organises the first SMA Research Conference, which will take place in Krakow, Poland, between 25th & 27th January 2018. We have an exciting programme and talks by most of the world experts in SMA: Key note: Where have we come, where do we go? Arthur Burghes Session 1: SMN function importance in the […]

    READ MORE